ORMP - オラメド・ファ―マシュ―ティカルズ (Oramed Pharmaceuticals Inc.)

ORMPのニュース

   Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Has Outstanding Potential  2022/06/24 11:30:00 Stocks Register
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares, rose in value on Thursday, 06/23/22, with the stock price up by 27.90% to the previous day’s close as strong demand from buyers drove the stock to $5.41. Actively observing the price movement in the last trading, the stock closed the session at $4.23, falling within a range of $4.335 … Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Has Outstanding Potential Read More »
   Mosaic Tumbles Around 10%, Here''s 71 Biggest Movers From Yesterday  2022/06/24 09:35:00 Benzinga
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT ) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offering. F-star Therapeutics, Inc. (NASDAQ: FSTX ) shares climbed 59.8% to close at $6.36 after Sino Biopharmaceutical''s invoX Pharma announced it will acquire the company for $7.12 per share. The acquisition values F-star at approximately $161 million. TDH Holdings, Inc. (NASDAQ: PETZ ) jumped 54.7% to close at $2.94. TDH Holdings recently announced a 1-for-20 reverse stock split. Vroom, Inc. (NASDAQ: VRM ) climbed 36.4% to close at $1.61. Rain Therapeutics Inc. (NASDAQ: RAIN ) surged 32.8% to close at $3.44. JonesTrading initiated coverage on Rain Therapeutics with a Buy rating and announced a price target of $17. Molecular Data Inc. (NASDAQ: MKD ) gained 32.2% to close at $0.69. Cardiff Oncology, Inc. (NASDAQ: CRDF ) jumped 31.6% to settle at $2.29. 22nd Century Group, Inc. (NASDAQ: XXII ) rose 31.1% to close at $2.57. 9 Meters Biopharma, Inc. (NASDAQ: NMTR ) jumped 31.1% to close at $0.3473. 9 Meters Biopharma recently announced an interim analysis of its Phase 3 study of Larazotide for celiac disease does not support trial continuation.
   Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Is Currently -620.09% Below Its 52-Week High, But Upside Potential Is Still There.  2022/06/11 13:00:00 Marketing Sentinel
In last trading session, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw 0.48 million shares changing hands with its beta currently measuring 2.03. Company’s recent per share price level of $4.38 trading at -$0.15 or -3.31% at ring of the bell on the day assigns it a market valuation of $161.05M. That closing price of ORMP’s stock is … Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Is Currently -620.09% Below Its 52-Week High, But Upside Potential Is Still There. Read More »
   Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Stock: Does It Have More Upside?  2022/06/01 14:00:00 Marketing Sentinel
In the last trading session, 1.51 million shares of the Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) were traded, and its beta was 2.03. Most recently the company’s share price was $4.63, and it changed around -$0.28 or -5.70% from the last close, which brings the market valuation of the company to $171.26M. ORMP currently trades at a … Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) Stock: Does It Have More Upside? Read More »
   Oramed granted U.S. combination therapy patent for oral insulin  2022/05/24 13:37:39 Seeking Alpha
Oramed Pharma (ORMP) said on Tuesday that the United States Patent and Trademark Office had granted a patent for methods and compositions for treating diabetes. The patent is for…
   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   26 Stocks Moving in Tuesday's Pre-Market Session  2021/03/23 11:15:23 Benzinga
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC ) rose 86.2% to $5.94 in pre-market trading. The surge follows Morgan Stanley disclosing in a filing with the U.S. Securities and Exchange Commission after the markets closed on Monday that it had increased its stake by about 5.2% in the Australian biotechnology company. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) shares rose 56.3% to $16.22 in pre-market trading after gaining over 13% on Monday. The company, last week, reported the formation of a joint venture with Oravax Medical to develop novel oral COVID-19 vaccines. China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD ) rose 33.3% to $1.48 in pre-market trading. BioLife Solutions Inc (NASDAQ: BLFS ) rose 16.7% to $45.00 in pre-market trading after the company reported better-than-expected Q4results. The company announced it will acquire Stirling Ultracold in an all-stock merger. Liquid Media Group Ltd. (NASDAQ: YVR ) rose 31.1% to $5.67 in pre-market trading after jumping over 30% on Monday. The company, last week, announced a $6 million registered direct offering of common shares.
   Së shpejti do të kemi vaksinën e parë si pilulë kundër koronavirusit  2021/03/22 20:31:37 Bota Sot
Provat klinike të vaksinës orale të coronavirusit mund të fillojnë së shpejti dhe të dhënat paraprake janë premtuese. Është një vaksinë e quajtur Oravax e zhvilluar nga kompania izraelito-amerikane, Oramed Pharmaceuticals dhe kompania…...
   This Indian pharma firm is developing oral COVID-19 vaccine in capsule form  2021/03/22 10:15:00 Business Today
Premas Biotech in collaboration with American firm Oramed Pharmaceuticals Inc had announced on March 19 that they are developing an oral COVID-19 vaccine candidate that has shown efficacy upon administration of a single dose
   Perusahaan Israel Buat Vaksin Oral untuk Covid-19  2021/03/22 06:15:15 Republika.co.id
REPUBLIKA.CO.ID, TEL AVIV — Perusahaan farmasi Israel, Oramed Pharmaceuticals Inc dilaporkan sedang bersiap meluncurkan uji klinis tahap pertama dari vaksin oral untuk mencegah infeksi virus corona jenis baru (COVID-19)….
   Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact - Stocks News Feed  2021/03/19 13:34:17 Stocks News Feed
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral COVID-19 vaccines. The new company, Oravax Medical Inc, will use Oramed’s proprietary POD oral delivery technology and Premas Biotech Pvt. Ltd.’s novel vaccine technology Oravax’s orally delivered COVID-19 vaccine candidate is a virus-like particle (VLP) triple antigen vaccine that targets… Read More »Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact
   Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact  2021/03/19 09:34:00 Benzinga
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral …
   Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol  2021/03/16 12:25:00 PR Newswire
NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized 25% of the 675 patients planned…
   ORAMED PHARMACEUTICALS (ORMP) INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Oramed Pharmaceuticals Inc. For Potential Securities Violations and Breaches of Fiduciary Duty  2021/03/02 13:01:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Oramed Pharmaceuticals Inc. (“Oramed” or the “Company”)(NASDAQCM: ORMP). If you currently own shares of Oramed and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/c
   Oral Biologics Market – Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc  2021/03/02 08:01:54 OpenPR
Oral Biologics Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities

calendar